Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: An update

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 5, 2016, Pages 545-553

  Kiang, Tony K L ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Mycophenolate; solid organ transplant; therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ALGORITHM; AREA UNDER THE CURVE; CONSENSUS; DRUG MONITORING; DRUG USE; GRAFT RECIPIENT; HUMAN; INCIDENCE; KIDNEY GRAFT; ORGAN TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; ADULT; DOSE RESPONSE; PROCEDURES;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGAN TRANSPLANTATION;

EID: 84964038016     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1170806     Document Type: Review

References (38)

1. Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014; 88:1351-1389.
2. Lexicomp clinical drug information [intranet database]. Mycophenolate. 2016 [cited 2016 Jan 23]. Available from: http://www.online.lexi.com
3. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005; 56:23-46.
4. Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando). 2011; 25:47-57.
5. van Gelder T, Van Schaik RH, Hesselink DA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014; 10:725-731.
6. Kuypers DR, van Gelder T. Therapeutic drug monitoring of mycophenolates: why make simple things complicated? Transplant Rev (Orlando). 2011; 25:45-46.
7. Le Meur Y, Borrows R, Pescovitz MD, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando). 2011; 25:58-64.
8. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008; 85:1675-1685.
9. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant. 2009; 9:1495-1499.
10. Cantarovich M, Brown NW, Ensom MH, et al. Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report. Transplant Rev (Orlando). 2011; 25:65-77.
11. Chen H, Chen B. Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol. 2014; 20:10715-10728.
12. Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients-a systematic review. Transplant Rev (Orlando). 2009; 23:171-177.
13. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999; 68:261-266.
14. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007; 7:2496-2503.
15. van Gelder T, Silva HT, De Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008; 86:1043-1051.
16. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009; 9:1607-1619.
17. Le Meur Y, Thierry A, Glowacki F, et al. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation. 2011; 92:1244-1251.
18. Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol. 2010; 5:1282-1289.
19. Fu L, Huang Z, Song T, et al. Short-term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, singlecenter cohort study in Chinese living-related kidney transplantation. Transpl Infect Dis. 2014; 16:760-766.
20. Sarangi SC, Reeta KH, Agarwal SK, et al. A pilot study on area under curve of mycophenolic acid as a guide for its optimal use in renal transplant recipients. Indian J Med Res. 2012; 135:84-91.
21. Ding C, Xue W, Tian P, et al. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? Int J Clin Pract Suppl. 2014; 181:10-16.
22. Ling J, Shi J, Jiang Q, et al. Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. Eur J Clin Pharmacol. 2015; 71:95-106.
23. Mourer JS, Hartigh J, van Zwet EW, et al. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation. 2012; 93:887-894.
24. Wang X, Qin X, Wang Y, et al. Controlled-dose versus fixed-dose mycophenolate mofetil for kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials. Transplantation. 2013; 96:361-367.
25. Daher Abdi Z, Essig M, Rizopoulos D, et al. Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach. Pharmacol Res. 2013; 72:52-60.
26. Bruchet NK, Ensom MH. Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review. Expert Opin Drug Metab Toxicol. 2009; 5:1079-1097.
27. Staatz CE, Tett SE. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet. 2011; 50:759-772.
28. Sommerer C, Muller-Krebs S, Schaier M, et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol. 2010; 69:346-357.
29. Mathew BS, Fleming DH, Annapandian VM, et al. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period. Ther Drug Monit. 2010; 32:136-140.
30. Capone D, Tarantino G, Kadilli I, et al. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant. 2011; 26:3019-3025.
31. Fleming DH, Mathew BS, Prasanna S, et al. A possible simplification for the estimation of area under the curve (AUC (0) (-) (1) (2)) of enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus. Ther Drug Monit. 2011; 33:165-170.
32. Poulin E, Greanya ED, Partovi N, et al. Development and validation of limited sampling strategies for tacrolimus and mycophenolate in steroid-free renal transplant regimens. Ther Drug Monit. 2011; 33:50-55.
33. de Winter BC, Monchaud C, Premaud A, et al. Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. Clin Pharmacokinet. 2012; 51:29-39.
34. Sánchez Fructuoso AI, Perez-Flores I, Calvo N, et al. Limited-sampling strategy for mycophenolic acid in renal transplant recipients reciving enteric-coated mycophenolate sodium and tacrolimus. Ther Drug Monit. 2012; 34:298-305.
35. Chaabane A, Aouam K, Ben Fredj N, et al. Limited sampling strategy of mycophenolic acid in adult kidney transplant recipients: influence of the post-transplant period and the pharmacokinetic profile. J Clin Pharmacol. 2013; 53:925-933.
36. Pawinski T, Luszczynska P, Durlik M, et al. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. Ther Drug Monit. 2013; 35:760-769.
37. Yamaguchi K, Fukuoka N, Kimura S, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the concentration- time curve treated in Japanese living-related renal transplant recipients with concomitant extended-release tacrolimus. Biol Pharm Bull. 2013; 36:1036-1039.
38. Langers P, Press RR, Inderson A, et al. Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation. Ther Drug Monit. 2014; 36:141-147.